"While lecanemab showed stability or improvement in nearly 83% of early Alzheimer’s patients in a real-world retrospective study, the absence of a control group means these outcomes cannot be definitively attributed to the drug’s efficacy."
Three years after lecanemab (Leqembi) received traditional FDA approval, marking a significant milestone as the first anti-amyloid antibody to achieve this status, its manufacturers, Eisai and Biogen, have released new data on its performance outside the controlled environment of clinical trials. The LEADER (Lecanemab in Early Alzheimer’s Disease) study, presented at the Alzheimer’s Association International Conference (AAIC) in London, offers a glimpse into how the treatment is being utilized in diverse clinical settings across the United States. The findings indicate that approximately 83% of enrolled patients with early Alzheimer’s disease remained stable or showed improvement over an average treatment period of 17 months. Specifically, the companies reported that 75.9% of patients remained stable, while 6.6% demonstrated improvement. These results were noted to be consistent across various demographic groups, including sex, race, ethnicity, and APOE genotype, suggesting a broad applicability of the drug’s observed effects.
The LEADER study, described as a three-year multicenter retrospective examination, was designed to assess the real-world utilization patterns, treatment persistence, transition to maintenance therapy, safety profiles, and ultimately, the cognitive and functional outcomes associated with lecanemab. The presentation also touched upon the established maintenance dosing regimen, which involves intravenous infusions every four weeks, and introduced initial findings regarding the newly developed at-home subcutaneous administration. This shift towards understanding real-world implementation is crucial because clinical trials, by design, enroll highly selected participants who may not fully represent the broader patient population encountered in everyday medical practice.
The rationale behind designing a retrospective real-world study like LEADER stems from the inherent limitations of controlled clinical trials. The CLARITY-AD trial, the pivotal study that led to lecanemab’s FDA approval in July 2023, involved 1,795 participants who met stringent eligibility criteria. Such trial populations are typically younger, healthier, and present with fewer co-existing medical conditions compared to the patients who ultimately receive a drug in clinical practice. Furthermore, trial cohorts are often less racially and ethnically diverse. LEADER, by contrast, draws data from actual clinical practice across numerous U.S. sites, allowing for the inclusion of patients who are generally more diverse, older, and medically complex. As previewed by Techtimes, the conference aimed to address critical questions that trials cannot: Who actually initiates treatment? Who remains on therapy? How do infusion schedules hold up in community-based settings? What are the practicalities of monitoring? The value of LEADER lies in its attempt to answer these implementation-focused questions, though these same characteristics also define its limitations.
It is imperative to approach the findings of a retrospective abstract with careful consideration, as the headline figures can be easily misinterpreted. LEADER is retrospective, meaning researchers analyzed existing patient records of those who had already undergone treatment. Crucially, the study lacks a control group; no participants were left untreated for comparison. Consequently, there is no direct way to ascertain what would have happened to these patients had they not received lecanemab. This absence of a comparator group is highly significant when interpreting figures such as "83 percent stable or improved." The progression of early Alzheimer’s disease varies considerably, and some individuals may experience slow decline over 17 months irrespective of treatment. Therefore, stability in this context cannot be definitively attributed to the drug. The finding primarily describes what occurred within the treated cohort rather than demonstrating a causal link.
Moreover, the definition of "stable" itself carries substantial weight, and the LEADER announcement does not fully elaborate on the specific criteria used. The threshold for stability, the instruments employed for measurement, and the methods for handling missing data all influence the reported percentage, details that are typically not included in a press release. The reported average treatment duration of 17 months also warrants attention, especially when viewed against the study’s three-year framing. While the study period spans three years post-approval, the average duration of treatment analyzed is less than half of that timeframe.
Retrospective designs are also susceptible to selection biases. Patients who tolerate the drug well and can manage biweekly infusions are more likely to remain on treatment and thus be included in follow-up outcome analyses. Conversely, patients who discontinue treatment early, experience amyloid-related imaging abnormalities (ARIA), or face logistical challenges in receiving infusions may be underrepresented in these outcome assessments. It is also important to note that LEADER was presented as a conference abstract in a "Developing Topics" session, meaning it has not yet undergone peer review or publication in a scientific journal. Furthermore, the study was conducted by the manufacturers of the drug, which is standard practice for such initial real-world data releases.
A crucial counterpoint to these company-sponsored findings exists within the broader scientific literature. Independent assessments of the anti-amyloid drug class have yielded notably different conclusions. A comprehensive Cochrane Review of anti-amyloid therapies for Alzheimer’s disease concluded that these treatments are not clinically effective. This finding emerged around the same time as the LEADER presentation and was framed by Techtimes as a significant backdrop to the Alzheimer’s Association International Conference. Cochrane reviews are distinguished by their synthesis of randomized evidence and their application of strict thresholds for determining clinical meaningfulness, a methodology distinct from describing outcomes within a treated cohort. The central debate revolves around whether the effect sizes observed in randomized trials, even when statistically significant, are substantial enough for patients and their families to perceive a tangible benefit. This question remains unsettled by studies lacking a control group, and a company-funded abstract does not definitively resolve it. Nevertheless, these observations do not render the LEADER study worthless; rather, they position it as evidence pertaining to the implementation of the drug rather than conclusive evidence of its efficacy.
For families considering lecanemab as a treatment option, the practical landscape remains largely unchanged by this latest announcement. Lecanemab is approved for individuals in the early stages of Alzheimer’s disease, encompassing mild cognitive impairment due to Alzheimer’s or mild Alzheimer’s dementia, with confirmed amyloid pathology. A known risk associated with the drug is amyloid-related imaging abnormalities (ARIA), which necessitates regular MRI monitoring on a defined schedule. The risk of ARIA is influenced by the patient’s APOE4 genotype, a factor that should be central to any discussion with a neurologist.
Encouragingly, the delivery burden of lecanemab is evolving. On July 13, 2026, the FDA approved a once-weekly subcutaneous autoinjector formulation for patients initiating treatment, with a commercial launch anticipated in late August through specialty pharmacies. This development promises greater convenience and potentially improved adherence for many individuals.
Anyone contemplating lecanemab treatment should engage in a thorough discussion with their neurologist. Key questions to address include the realistically expected magnitude of benefit, the detailed monitoring schedule, specific triggers for discontinuing treatment, and the total out-of-pocket costs, including those associated with necessary imaging. MedicalDaily will continue to report on the peer-reviewed publication of the LEADER data, any independent real-world analyses that emerge, and further findings related to the subcutaneous administration of lecanemab.
Frequently Asked Questions
What did the LEADER study find?
The LEADER study reported that nearly 83% of enrolled patients with early Alzheimer’s disease remained stable (75.9%) or improved (6.6%) over an average of 17 months while receiving lecanemab.
Is the LEADER study a clinical trial?
No, the LEADER study is a retrospective real-world study that analyzed records from U.S. clinical practice. It did not include a control group for comparison.
Has the LEADER study been peer-reviewed?
No, the LEADER study was presented as a conference abstract at AAIC 2026 and has not yet been published in a peer-reviewed journal.
Does the LEADER study prove that lecanemab works?
No, because the study lacks an untreated comparison group, the observed stability over 17 months cannot be definitively attributed to the drug’s efficacy.
Why was a study like LEADER conducted?
The study was designed to gather information on how lecanemab performs in older, more diverse, and medically complex patients than those typically enrolled in clinical trials. It also aimed to track treatment persistence, monitoring practices, and safety in real-world clinical settings.
Who funded the LEADER study?
The study was funded by Eisai and Biogen, the companies that co-commercialize lecanemab.
What questions should families ask their neurologist about lecanemab?
Families should inquire about the expected magnitude of benefit, the MRI monitoring schedule, the risk of ARIA including their APOE4 status, what specific factors would necessitate stopping treatment, and the total out-of-pocket costs associated with the therapy.
